Highlights
- Lincoln Pharmaceuticals shares fell over 11% despite reporting profitable Q4 FY26 results.
- The stock slipped below its 21-day SMA amid profit booking after a recent rally.
- Support levels near INR 637.40 and INR 603.86 will remain crucial for trend stability.
Overview
Lincoln Pharmaceuticals (NSE: LINCOLN) witnessed sharp selling pressure on May 29, with the stock declining 11.50% to INR 670.95. The fall came immediately after the company announced its March 2026 quarter results, surprising investors given that the company remained profitable during the period.
The stock opened at INR 687.95, touched an intraday high of INR 697.85, and later declined to a low of INR 660.00 as selling intensified. The correction follows a strong rally that had pushed the stock toward the INR 760 zone in recent weeks, suggesting that investors may have used the earnings event to book profits.
Fundamental View
Lincoln Pharmaceuticals reported consolidated total income of INR 18,308.20 lakh for the quarter ended March 2026. Profit before tax stood at INR 1,670.26 lakh, while net profit came in at INR 1,163.46 lakh. Earnings per share were reported at INR 5.81.
While the company remained profitable, the earnings performance may not have matched elevated market expectations following the stock's recent upmove. As a result, traders appeared to lock in gains, leading to a sharp decline despite the positive bottom-line performance.
Technical View
Lincoln Pharmaceuticals closed near INR 670.95, falling below its 21-day SMA of INR 688.56, reflecting a weaker near-term technical structure. Recent price action indicates a sharp reversal after a strong rally, with the stock witnessing aggressive profit booking near higher levels.
The decline has also pulled the stock away from recent highs, increasing the importance of nearby support zones. Unless the stock reclaims the short-term moving average, volatility may remain elevated in the near term.
Momentum Indicator
The 14-day RSI declined to 48.82, slipping below the neutral 50 mark and indicating fading momentum. The indicator suggests that bullish momentum has weakened considerably following the recent correction, although the stock is not yet in oversold territory.
Key Technical Levels
Lincoln Pharmaceuticals is trading near INR 670.95. Immediate support is placed around INR 637.40, while the next important support zone is located near INR 603.86. On the upside, resistance is seen around INR 704.50, followed by a stronger hurdle near INR 738.05. A sustained move above resistance levels could improve sentiment, while a break below support may keep the stock under pressure.
Risks to Watch
- Continued profit booking after recent rally.
- Failure to reclaim the 21-day SMA.
- Weak sentiment across pharmaceutical stocks.
- Increased volatility around earnings reactions.
Summary
Lincoln Pharmaceuticals reported consolidated revenue of INR 18,308.20 lakh and net profit of INR 1,163.46 lakh for the March 2026 quarter. Despite remaining profitable, the stock witnessed heavy selling as investors booked profits after a strong rally. Technically, the stock has slipped below its 21-day SMA, while RSI momentum has weakened. Support levels near INR 637.40 and INR 603.86 remain important, while resistance is placed at INR 704.50 and INR 738.05.
FAQs
- Why did Lincoln Pharmaceuticals shares fall after reporting results?
The decline appears linked to profit booking following a strong rally despite the company reporting profitable quarterly earnings.
- What are the key support levels for Lincoln Pharmaceuticals?
Immediate support is near INR 637.40, while the next important support level is around INR 603.86.
- What resistance levels should investors monitor?
Key resistance levels are located around INR 704.50 and INR 738.05.